

Review

COMPLEMENTARY CANCER THERAPY: A SYSTEMATIC REVIEW OF PROSPECTIVE CLINICAL TRIALS ON ANTHROPOSOPHIC MISTLETOE EXTRACTS

G. S. Kienle, H. Kiene

Institute for Applied Epistemology and Medical Methodology, Bad Krozingen, Germany

Abstract

Background: Anthroposophic Mistletoe therapy is a widely used complementary cancer treatment.

Objective: To evaluate prospective clinical trials on the effectiveness of anthroposophic mistletoe therapy for cancer.

Design: Systematic review.

Material and Methods: Search of 9 electronic databases, reference lists and extensive expert consultations. Criteria-based assessment of methodological study quality.

Results: 16 randomized (RCT) and 9 non-randomized (N-RCT) controlled trials were identified that investigated mistletoe treatment of malignant diseases. Statistically significant benefit for survival was reported in 8 of 17 trials (in 5 of 10 RCTs), for disease-free survival and tumour recurrence in none of 2 RCTs, for remission of tumour and malignant effusion in 1 RCT and 1 N-RCT of 4 controlled trials, for quality of life (QoL) in 3 of 5 RCTs, and for QoL and reduction of side effects of cytoreductive therapies (chemotherapy, radiation or surgery) in 5 of 7 trials (3 of 5 RCTs). Methodological quality of the controlled trials differed substantially; some had major limitations while others were reasonably well conducted. 12 single-arm cohort studies were identified. 5 of 7 studies found substantial tumour remission in various cancers, one study reported remission of CIN, and 4 studies remission of malignant pleural effusion or ascites. Quality of reporting in cohort studies was mostly reasonably good. Mistletoe application was well tolerated.

Conclusions: Regarding quality of studies and consistency of results, the best evidence for efficacy of mistletoe therapy exists for improvement of QoL and reduction of side effects of cytotoxic therapies (chemotherapy, radiation). Survival benefit has been shown but not beyond critique. Tumour remissions are described in cohort studies that investigate the application of high dose or local mistletoe extracts. As several reasonably well-conducted studies indicate beneficial effects, further properly designed trials should be encouraged to investigate clinical efficacy and its possible dependency on the mode of application.

Key words: Clinical trials, systematic review, mistletoe, *Viscum album*, neoplasms

INTRODUCTION

Complementary and alternative medicine (CAM) is popular among cancer patients; across Europe 40% (15-73%) use some form of CAM, mostly herbal medicine. [1] Mistletoe extracts (*Viscum album* L., VAE) are the most frequently prescribed CAM cancer therapies in Central Europe [2]. Up to two thirds of cancer patients in Germany and Austria receive CAM, primarily mistletoe extracts. [3;4]

Mistletoe treatment for cancer was introduced in 1920 by Steiner and Wegman, founders of Anthroposophic Medicine (AM). [5] AM is a CAM system, and is practised worldwide, particularly in Central Europe. [6;7] AM mistletoe preparations – Abnobaviscum, Helixor, Iscador (labelled as “Iscar” in the US), Iscucin, Isorel – are used not only within but also widely outside AM. They are extracts from defined parts of *Viscum album* L., i.e. fresh leafy shoots and berries. These preparations are available from different host trees such as fir (Abies, A), oak (Quercus, Qu), apple tree (Malus, M), pine (Pinus, P), elm (Ulmus, U), and others. Route of application and dosage are varied individually, depending on the patient’s reaction and stage of disease. AM mistletoe is used in all stages of disease, either alone or in combination with chemotherapy, radiation therapy, or hormone therapy.

Biological and pharmacological properties of VAE have been subject to extended scientific investigations (overview in [8;9]). Several pharmacologically active compounds have been isolated, such as mistletoe lectins (ML I, II and III) [10], viscotoxins [11;12], oligo- and polysaccharides [13;14], lipophilic extracts [15] and several others [8]. The most prominent properties of VAE are their cytotoxic and growth-inhibiting effects on a variety of human tumour cell lines, lymphocytes and fibroblasts in vitro [8]. The cytotoxic effects of VAE are mainly due to the apoptosis-inducing mistletoe lectins [16-18], while the viscotoxins induce necrotic cell death [18;19]. VAE are also recognized for their immune modulating activity. *In vitro* and *in vivo* studies have demonstrated activation of monocytes/macrophages, granulocytes, natural killer (NK) cells, T-cells (especially T-helper-cells) and the induction of various cytokines [8]. VAE also possess DNA stabilizing properties. [20-22] In animals, VAE displays potent antitumoural effects when adminis-

tered either directly into the tumour or systemically. [8; 9]

Clinical efficacy of mistletoe therapy has been the subject of controversial debate. Because of its widespread use and because of increasing research activity, systematic review of clinical mistletoe studies is important. Most reviews are outdated or incomplete (e.g. [23-28]). Of the recently published reviews, one focused on non-AM mistletoe extracts only [27], one missed most of the RCTs on AM mistletoe extracts [28], and one [29] is being incorporated into the following.

This review was initiated by the Complementary Medicine Evaluation Programme (Programm Evaluation der Komplementärmedizin – PEK), a research initiative of the Swiss Parliament, covering HTA reports on five CAM methods, including AM [6;7]. Out of 197 clinical studies on AM therapies, 97 prospective and retrospective studies investigated mistletoe in cancer and other neoplasms [7]. The present review is restricted to prospective clinical studies on AM mistletoe application in cancer only, addressing the following questions:

Do prospective clinical trials provide evidence for the effectiveness of mistletoe therapy in relation to survival, tumour remissions (including malignant effusion), quality of life (QoL), or reduction of side effects from cytoreductive therapies in cancer patients? Can the effect size be estimated by quantitative data synthesis?

MATERIAL AND METHODS

Methods were predefined in a protocol.

SEARCH STRATEGY

We used a systematic process to search the following databases for clinical trials: AMED, Biosis Previews, Cinahl, Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, The NHS Economic Evaluation Database, Health Technology Assessment Database), Embase, Medline/Premedline, NLM Gateway, Science Citation Index, National Centre for Complementary and Alternative Medicine, private databases; from inception of these databases to June 2006 using the terms (ANTHROPOS? OR MISTLETOE OR VISCUM? OR MISTEL? OR ISCADOR? OR ISCAR OR HELIXOR OR ABNOBA? OR ISCUCIN OR ISOREL OR VISOREL OR ?SOREL OR WELEDA OR WALA) AND (STUDY? OR STUDIE? OR TRIAL OR EVALUAT? OR RANDOM? OR INVESTIG? OR COHORT? OR KOHORT? OR OUTCOME? OR REVIEW OR UEBERSICHT OR METANALYS? OR META(W)ANALYS?) The reference list from each potentially eligible study, relevant review article and textbook was checked, and experts in the field and manufacturers of mistletoe preparations were contacted for additional reports.

SELECTION

The following selection criteria were used for inclusion of studies in the analysis: (I) prospective random-

ized or non-randomized controlled clinical trial, or prospective single-arm cohort study (e.g. phase II trial); (II) study population with cancer, including cervical intra-epithelial neoplasm (CIN); (III) intervention group treated with anthroposophic mistletoe preparation; (IV) clinically relevant outcome (i.e. survival, disease-free interval, remission, relapse, QoL, or reduction of side effects or immune suppression during cytoreductive therapy); (V) completion of study; (VI) published or unpublished. Studies were excluded if they: only measured toxicity or tolerability (phase I trial), only measured stimulation of immunological parameters, or were not conducted on cancer patients. There were no restrictions on language.

VALIDITY ASSESSMENT AND DATA ABSTRACTION

Criteria-based analysis was performed on the selected studies to assess their methodological quality. Analyses were performed independently by two reviewers (GK, HK). There were no major differences in study assessment; disagreements were resolved by discussion. Criteria for assessing strength of evidence in controlled trials were adapted from the National Health Service Centre for Reviews and Dissemination [30] and from criteria for good methodology as already applied in earlier reviews on mistletoe trials [24;29]. Quality criteria were adjusted for cohort studies [6]. Criteria were rated as “+” = adequately fulfilled, “(+)” = partly fulfilled, “(-)” = little fulfilled, “-” = not fulfilled. Data were abstracted by one reviewer (GK) and checked by the second reviewer (HK). When necessary, primary authors of the trials were contacted for additional information.

For ranking the quality of the studies (cf. Table 1 and Table 3) we computed a summary score with 3 for +, 2 for (+), 1 for (-), and 0 for - respectively. The function of this ranking is only to provide a quick, summary reference to the methodological quality of the studies. It does not claim precision since it neither presupposes equivalence of rating intervals nor numerical equality among the different criteria.

RESULTS

Figure 1 summarizes the process of identifying eligible clinical trials (for more details see [6;7]). 37 trials met the inclusion criteria: 16 RCTs, 9 N-RCTs, and 12 single-arm cohort studies. Of the 37 trials, 34 were published (three of these only as an abstract [31-33]), one study was retrieved as a doctoral dissertation [34], and two were unpublished reports [35;36]. Two further trials [37;38], conducted in Poland, were excluded from this review because of severe validity concerns: a collaborating scientist questioned the alleged randomization of treatment allocation, and no information could be received from the authors to clarify this question.

CHARACTERISTICS OF INCLUDED TRIALS

Table 1 - Table 6 show characteristics of the trials. Settings of the trials were academic hospitals, large community hospitals, and specialized cancer hospitals; three trials were done in cancer rehabilitation centres.




Fig. 1. Identification of eligible prospective clinical cancer trials on anthroposophic mistletoe preparations (updated HTA-report [6; 7])

The studies were conducted in Germany ($n = 14$), Austria ($n = 6$), Egypt ($n = 4$), Italy ($n = 2$), Israel ($n = 2$), Switzerland ($n = 2$), Romania ($n = 2$), China ($n = 1$), Denmark ($n = 1$), South Korea ($n = 1$), or in more than one European country ($n = 2$). 22 trials were conducted in one, 15 in more than one centre. One of the controlled [39] and four of the cohort studies [33;36;40;41] were conducted in an AM hospital, the other ones in non-AM institutions.

Controlled trials:

16 RCTs (see Table 1) included 2602 participants, 9 N-RCTs (see Table 2) included more than 2512 participants (the sample size of one control group was not published). Cancer sites studied were: breast ($n = 10$), lung ($n = 8$), colon and rectum ($n = 5$), stomach ($n = 3$), melanoma ($n = 2$), ovary ($n = 2$), genital ($n = 2$), head and neck ($n = 1$), gastrointestinal ($n = 1$), and malignant pleural effusion ($n = 1$). Stages ranged from early detected to advanced disease. 20 trials had two arms, four trials had three arms, one trial consisted of two overlapping parts with three and four arms respectively, with two of the four arms used for analysis of mistletoe efficacy. Endpoints were: survival ($n =$

17), tumour remission or recurrence ($n = 5$), pleurodesis ($n = 1$), quality of life or coping with disease (QoL, $n = 5$), QoL, physical condition and reduction of side effects of chemotherapy, radiotherapy or surgery ($n = 7$). Length of follow-up depended on primary outcome, varying from three days in one trial [39] to usually months or years (survival).

All treatment groups received conventional care (COM) when indicated. In nine trials mistletoe was administered concurrently with chemotherapy, radiotherapy or surgery [35;39;42-48]; seven of the trials assessed reduction of side effects from these cytoreductive therapies [35;39;44-48]. In 18 trials mistletoe therapy was used at least partly in an adjuvant setting after surgery or radiotherapy [39;44-46;48-60].

The applied mistletoe remedies were Iscador, Helixor, or Isorel. Host tree specification of these remedies (usually depending on cancer site, and sex of patient) was often not mentioned. Dosage mostly followed recommendations of the manufacturer, starting with low doses and increasing to the maximum tolerated dosage; one trial treated according to lectin-content (1ng/kgKG) [61]. Mistletoe was injected subcutaneously except in three studies employing intravenous

Table 1. Quality of Randomized Controlled Mistletoe Trials (ordered by decreasing quality).

Author, Year	Quality Criteria Fulfilled in Studies ^I											Partici- pants	AR ^{II}
	A)	B)	C)	D)	E)	F)	G)	H)	I)	J)	K)		
Piao 2004 [45]	+	+	-	(-)	+	+	+	(+)	+	+	+	233	4%
Auerbach 2005 [46]	+	-	(+)	(+)	+	-	+	(+)	+	(+)	+	23	17-30%
Grossarth 2001 [59]	+	+	-	(-)	+	+	+	(-)	+	+	-	34	0%
Dold 1991 [66]	+	+	-	-	+	(-)	+	(+)	+	+	(-)	408	17%
Lange 1985 [35]	+	+	-	(-)	+	(-)	+	(+)	+	+	-	68	35%
Borrelli 2001 [61]	+	-	(+)	(+)	+	+	(+)	+	(-)	(+)	-	30	0%
Grossarth 2001 [59]	+	+	-	(-)	+	(-)	+	(-)	+	+	-	98	20%
Kleeberg 2004 [60;67]	+	+	-	(-)	(-) ^{III}	(-)	(+)	+	(+)	(+)	(+)	204 (830)	24%
Salzer 1991 [49]	+	(+)	-	(-)	(+)	(-)	+	(+)	(+)	+	-	218	16%
Douwes 1986 [42]	+	-	-	(-)	+	+	+	+	-	(+)	-	60	0%
Gutsch 1988 [51]	+	-	-	(-)	+	(-)	+	+	(+)	+	-	692	20%
Salzer 1979, 1983 [56-58]	+	-	-	(-)	+	-	+	+	(+)	(+)	-	320	57%
Cazacu 2003 [44]	(+)	-	-	(-)	+	+	(+)	(+)	(-)	-	-	64	not shown
Salzer 1987 [55]	+	(+)	-	(-)	+	-	+	-	-	-	-	50	48%
Enesel 2005 [47] ^{IV}	+	-	-	-	(+)	-	(+)	(-)	(-)	(-)	-	70	45%
Kim 1999 [32]	+	-	-	-	(-)	-	(+)	(+)	(-)	(-)	-	30 ^V	13%

^I A) Protection against selection bias, especially by adequate randomization

B) Minimization of heterogeneity by pre-stratification or matching

C) Protection against observer bias by blinding of patient, care provider, and outcome assessor

D) Protection against performance (treatment) bias by standardization of care protocol, documentation of all co-interventions, blinding of patients and care providers

E) Protection against measurement (detection) bias by standardization of outcome assessment

F) Protection against attrition (exclusion) bias, lost patients <10% or by intention-to-treat analysis (including non-adherers as randomized) plus per-protocol analysis (excluding non-adherers) in combination with sensitivity analysis, and by comparison of prognostic characteristics of lost patients and compliers

G) Effect measurement relevant and well described

H) Well described intervention, patient characteristics, disease (diagnosis, stage, duration), previous therapy

I) Well described study design

J) Well described results

K) Data quality assured by GCP-ICH-guidelines, especially by monitoring

^{II} AR: attrition rate (dropouts, protocol deviations, withdrawals, patients did not receive treatment as allocated).

^{III} Primary endpoint (disease-free survival) was prone to measurement bias (see discussion or [29]); secondary endpoints were resistant to measurement bias (overall survival), or were not published (quality of life).

^{IV} Essential information in a supplementary statement

^V Discrepancy in patient numbers in two presentations (30 and 33), with corresponding discrepancy of results

infusion [39;44] or intrapleural instillation [32]. Treatment duration depended on primary endpoint and related follow-up, ranging from one single application (in one trial [39]) to repeated applications over months and years, often with individually varying length within trials. Exact treatment duration, however, was often not specified. Control groups received either no further treatment (n = 18), additional placebo application (n = 3), doxycyclin (n = 1), Lentinan (n = 1), BCG (n = 1), or partly hormones (n = 1). Two trials had double-blinded treatment application [46;61]. Besides the mistletoe extracts, AM was not part of any study treatment except perhaps in one N-RCT on surgery-associated inhibition of granulocyte function [39] that was partly conducted in an AM hospital.

We found substantial heterogeneity of the studies in terms of intervention, patient characteristics, clinical diagnosis, measured outcomes, design, methodological quality and potential positive and negative biases. We therefore considered a quantification of effect size by combining results to be unreliable and decided on a non-quantitative synthesis and discussion.

Single-arm cohort studies:

Twelve prospective cohort studies (see Table 6) included 251 patients. Cancer sites studied were colorectal (n = 1), pancreas (n = 1), hepatocellular carcinoma (HCC, n = 1), breast (n = 2), brain (n = 1), kidney (n = 1), follicular Non-Hodgkin's lymphoma (FL, n = 1), and CIN (n = 1). Furthermore, malignant pleural effusion (n = 2) and malignant ascites (n = 2) were investigated. Tumour stages were advanced or inoperable, except in FL (all stages) or CIN. Six trials were on solid tumours and one on FL; four of these included patients who all [31;62;63], or some of whom [41], had received conventional pre-treatment, and had mostly been resistant especially to chemotherapy; the two other trials included patients with inoperable or disseminated disease who had received no prior chemo- or hormone therapy [64;65]. One trial combined mistletoe extract with gemcitabine in inoperable pancreatic cancer [33]. All 12 studies assessed remission of solid tumours, of FL, or of malignant effusion; eight of them also reported QoL or symptomatic relief. The mistletoe remedies were *Abnobaviscum* (partly *Viscum fraxini*), *Iscador*, or *He-*

Table 2. Quality of Non-randomized Controlled Mistletoe Trials (ordered by decreasing quality).

Author, Year	Quality Criteria Fulfilled in Studies ^{II}											Partici- pants	AR ^{II}	Design/control for confounding
	A)	B)	C)	D)	E)	F)	G)	H)	I)	J)	K)			
Grossarth 2001 [59]	(+)	+	-	(-)	+	+	+	-	+	+	-	792	3.5%	Prospective pair -matching
Büssing 2004 [39]	(-) ^{VI}	-	-	(-)	+	+	(+)	(+)	(+)	+	+	105	7%	Comparison of two different hospitals. Pair-matching for analysis
Salzer 1978 [53]	-	-	-	(-)	+	+	+	(+)	+	(+)	-	77	0%	Treatment allocation by type of hospital referring the patient to surgery
Douwes 1988 [43]	-	-	-	(-)	+	+	+	+	-	+	-	40	3%	Planned as an RCT, however, computer error occurred
Von Hagens 2005 [48]	-	-	-	(-)	+	(-)	+	+	(+)	(+)	-	66	11 %	Self-selected treatment allocation
Schuppli 1990 [52]	(+)	-	-	(-)	+	(-)	+	(-)	-	-	-	198	not shown	Prognostic disadvantage for mistletoe group at study begin
Salzer 1987 [55]	(+)	-	-	(-)	+	-	+	-	-	(+)	-	155	not shown	Alternating treatment allocation
Fellmer 1966 [54]	-	-	-	(-)	+	-	+	+	-	-	-	924	16%	Treatment allocation by neutral attending physician
Majewski 1963 [50]	(+)	-	-	(-)	+	-	+	-	-	-	-	^{VII}	not shown (I: 15%) ^{VIII}	Alternating treatment allocation

Abbreviations as in Table 1. ^{VI}Propensity Score and Matching for final analysis ^{VII}Number of study patients not indicated; mistletoe group included 155 patients ^{VIII}Numbers are given only for mistletoe group

lixor. They were applied subcutaneously (n = 7), intratumourally (n = 2), intrapleurally (n = 2), or intraperitoneally (n = 2). Dosage depended on mode of application. Of the seven trials on solid tumours or FL, three started with high dosage and applied it constantly once per week; three other trials started with low dosages, increasing them successively, and the seventh trial applied increasing dosages intratumorally by endoscopic, ultrasound-guided, fine-needle injection [33]. The trial on CIN constantly applied a lower dosage. For intrapleural and intraperitoneal (repeated) application, mistletoe extracts were diluted in 5-15 or 100 ml solution respectively. Treatment durations and follow-up ranged from weeks to, most commonly, months or years.

QUALITY OF STUDIES

Table 1, Table 2 and Table 6 summarize the validity assessment. Methodological quality differed substantially. Some studies had major limitations in quality of design, conducting and reporting, while others were reasonably well conducted (Table 1, Table 2). During recent years study quality has markedly increased in most trials. In the cohort studies, study quality was reasonably good except in an unpublished report [36] and in the abstract publications [31;33] with too little information.

STUDY RESULTS

Main study results are shown in Table 3 - Table 6. On *survival* (Table 3): Out of 17 controlled trials, eight

(5 of 10 RCTs) had statistically significant positive results [44;51;53;54;56-59], eight (4 of 10 RCTs) positive trends [42;43;49;50;52;55;66], one RCT no effect [60].

On *disease-free interval and recurrence* (Table 4): Out of two RCTs, one had a negative trend [60], one no effect [49].

On *remission of tumour and malignant effusion* (Table 4): Out of four controlled trials (3 RCTs, 1 N-RCT), one N-RCT reported a statistically significant positive effect [43], one RCT a positive trend [66], one no effect [42]; one trial on malignant pleural effusion found significantly higher remissions with mistletoe than with doxycyclin [32]. Of 12 cohort studies (Table 6), five reported remission of solid tumours or of FL in 22-62% of patients, three reported remission of malignant effusion in 70-88% of patients, one an increase of interval between two successive paracenteses after mistletoe instillation, one reported remission of CIN in 68% of patients, and two reported stable and progressive disease, but no tumour remission. Time to remission (CR) of solid tumours was 4-6 months in two trials [63;64]. Concurrent conventional cytoreductive therapy was explicitly given in only two cohort studies, one with substantial [33] and one with no tumour remission [65].

On *QoL and coping* (Table 5): Out of five RCTs, three found a statistically significant benefit [59;61;66], one RCT did not report the results [60;67]. (Six further trials investigated QoL related to chemotherapy and radiation – see below.) Of eight cohort trials, five reported improved, one reported decreasing QoL, and

Table 3. Controlled Trials on Mistletoe Treatment in Cancer: Survival (RCTs and N-RCTs each ordered by decreasing quality. See Table 1 and Table 2).

Author, Year	Site	Stage	Intervention (evaluable patients)	Survival Outcomes	5-year survival	Others	P or CI
				Mean (Months) partly censored	Median (Months)	Hazard ratio	
Randomized controlled trials							
Grossarth 2001 [59]	Breast	IIIA-IIIB	<ul style="list-style-type: none"> • Iscador (17) • None (17) 	<ul style="list-style-type: none"> • 57.5 • 28.9 	<ul style="list-style-type: none"> • 7.5 • 2.8 		P=0.02
Dold 1991 [66]	Lung	All stages	<ul style="list-style-type: none"> • Iscador U or Qu, c.Hg. (114) • Placebo (vitamin B) (113) • Polyerga (110) 		<ul style="list-style-type: none"> • 9.1 • 7.6 • 9.0 		<ul style="list-style-type: none"> • n.s. (p=0.24) • n.s. (p=0.13)
Grossarth 2001 [59]	Breast, lung, colon, rectum, stomach	All stages	<ul style="list-style-type: none"> • Iscador (39) • None (39) 	<ul style="list-style-type: none"> • 42 • 29 	<ul style="list-style-type: none"> • 30 • 29 		P=0.04
Kleeberg 2004 [60;67]	Melanoma	High risk primary ($\geq 3\text{MM}$) or LN+	<ul style="list-style-type: none"> • Surgery, Iscador M (102) • Surgery, IFN-α (240) • Surgery, IFN-γ (244) • Surgery (244/102) 			<ul style="list-style-type: none"> • 1.21 • 0.96 • 0.87 	<ul style="list-style-type: none"> • n.s. (CI: 0.84-1.75) • n.s. (CI: 0.76-1.21) • n.s. (CI: 0.69-1.10)
Salzer 1991 [49]	Lung	I-IV	<ul style="list-style-type: none"> • Surgery, Iscador (87) • Surgery (96) 		<ul style="list-style-type: none"> • 33 • 31 		n.s.
Douwes 1986 [42]	Colon, rectum	Advanced	<ul style="list-style-type: none"> • 5FU/FA, Helixor (20) • 5FU/FA, Ney Tumorin (20) • 5FU/FA (20) 	Responder non-Respon. <ul style="list-style-type: none"> • 27 12 • 24 12 • 14 5 			not shown
Gutsch 1988 [51]	Breast	T1-3, N0-3, M0	<ul style="list-style-type: none"> • Surgery, radiation^I, Helixor (192) • Surgery, radiation^I, CMF (177) • Surgery, radiation^I (274) 		n.a. ^{II}		<ul style="list-style-type: none"> • P=0.048 • (P=0.025)
Salzer 1979, 1983 [56-58]	Stomach	II-III	<ul style="list-style-type: none"> • Surgery, Iscador (62) • Surgery (75) 	Lymph node + - <ul style="list-style-type: none"> • 25 55 • 18 45 	LN + - <ul style="list-style-type: none"> • 22 n.a.^{II} • 11 40 		LN + - P<0.05 n.s.
Cazacu [44]	Colon, rectum	Dukes C or D	<ul style="list-style-type: none"> • Surgery, 5-FU, Isorel A (29) • Surgery, 5-FU (21) • Surgery (14) 	Dukes D <ul style="list-style-type: none"> • 17 • 7 • 15 	Dukes C <ul style="list-style-type: none"> • 25 • 18 • 17 		P<0.05 (for D and C)
Salzer 1987 [55]	Lung	I (II)	<ul style="list-style-type: none"> • Surgery, Iscador (12) • Surgery (14) 	<ul style="list-style-type: none"> • 117 • 34.5 			not shown

Table 3. (continued)

Author, Year	Site	Stage	Intervention (evaluable patients)	Survival Outcomes	P or CI				
				Mean (Months) partly censored	Median (Months)	Hazard ratio	5-year survival	Others	
Non-randomized controlled trials									
Grossarth 2001 [59]	Breast, lung, colon, rectum, stomach	All stages	<ul style="list-style-type: none"> • Iscador (396) • None (396) 	<ul style="list-style-type: none"> • 50.8 • 36.6 	<ul style="list-style-type: none"> • 44 • 32 				P<0.001
Salzer 1978 [53]	Lung	I-III	<ul style="list-style-type: none"> • Surgery, Iscador (37) • Surgery (40) 		<ul style="list-style-type: none"> • 63 • 10 			<ul style="list-style-type: none"> • 6-year survival • 38% • 15% 	P<0.01
Douwes [43]	Colon, rectum	Advanced	<ul style="list-style-type: none"> • 5FU/FA, Helixor (19) • 5FU/FA (20) 		<ul style="list-style-type: none"> • 26 • 14 				n.s. (P=0.063)
Schuppli 1990 [52]	Melanoma	Not specified	<ul style="list-style-type: none"> • Surgery, Iscador P. c. Hg (84) • Surgery, BCG (114) 		n.a. ^{II}		<ul style="list-style-type: none"> • ~86% • ~72% 		not shown
Salzer 1987 [55]	Breast	I-III	<ul style="list-style-type: none"> • Surgery, Iscador, (76) • Surgery, radiation, hormone (79) 					<ul style="list-style-type: none"> • Alive 1985 • 29% • 24% (after 11-14 years)	not shown
Fellmer 1966 [54]	Cervix	I-III	<ul style="list-style-type: none"> • Radiation, Iscador (81) • Radiation (709) 				<ul style="list-style-type: none"> • 83% • 69% 		P=0.05
Majewski 1963 [50]	Genital	All stages	<ul style="list-style-type: none"> • Surgery^I, radiation^I, Iscador (155) • Surgery^I, radiation^I (not shown) 					Disease-specific survival partly improved	not shown

CMF: Cyclophosphamid, Methotrexat, 5FU; 5FU: 5-Fluorouracil; FA: Folic acid; P (p-value), CI (95%-confidence interval): Statistical significance of difference between mistletoe (or other verum) and control group; n.s.: not statistically significant; I Co-intervention (i.e. radiation) applied to part of the group; II n.a.: not applicable since more than 50% alive at study termination; “•”-outcomes relate to corresponding “•”-treatment group.

Table 4. Controlled Trials on Mistletoe Treatment in Cancer: Tumour Behaviour or Pleurodesis (RCTs and N-RCTs each ordered by decreasing quality. See Table 1 and Table 2)

Author, Year	Site	Stage	Intervention (evaluable patients)	Tumour or pleural effusion	Disease-free interval, Hazard ratio	Recurrence	P or CI
Randomized controlled trials							
Dold 1991 [66]	Lung	All stages	<ul style="list-style-type: none"> • Iscador U or Qu, c.Hg. (114) • Placebo (vitamin B) (113) • Polyerga (110) 	Complete resp. overall regression ^I <ul style="list-style-type: none"> • 4% 26% • 3% 20% • 2% 19% 			<ul style="list-style-type: none"> • n.s. (p=0.1) • (n.s. p=0.5)
Kleeberg 2004 [60;67]	Melanoma	High risk primary (≥3MM) or LN+	<ul style="list-style-type: none"> • Surgery, Iscador M (102) • Surgery, IFN-α (240) • Surgery, IFN-γ (244) • Surgery (244/102) 		<ul style="list-style-type: none"> • 1.32 • 1.04 • 0.96 		<ul style="list-style-type: none"> • n.s. (0.93-1.87) • (n.s. 0.84-1.30) • (n.s. 0.77-1.2)
Salzer 1991 [49]	Lung	I-IV	<ul style="list-style-type: none"> • Surgery, Iscador (87) • Surgery (96) 			<ul style="list-style-type: none"> • 50% • 55% 	n.s.
Douwes 1986 [42]	Colon, rectum	Advanced	<ul style="list-style-type: none"> • 5FU/FA, Helixor (20) • 5FU/FA, Ney Tumortin (20) • 5FU/FA (20) 	Complete resp. partial response <ul style="list-style-type: none"> • 15% 35% • 15% 25% • 15% 30% 			not shown
Kim 1999 [32]	Pleural effusion ^{II}	Advanced	<ul style="list-style-type: none"> • Helixor (11) • Doxycyclin, Meperidin, Lidocain (15) 	Complete resp. partial response ^{III} <ul style="list-style-type: none"> • 81% 9% • 40% 26% 			P<0.05
Non-randomized controlled trials							
Douwes 1988 [43]	Colon, rectum	Advanced	<ul style="list-style-type: none"> • 5FU/FA, Helixor (19) • 5FU/FA (20) 	Complete partial minimal resp. 16% 37% 26% 0% 30% 20%			“significant”, p-value not shown

5FU: 5-Fluorouracil; FA: Folic acid; P (p-value), CI (95%-confidence interval): Statistical significance of difference between mistletoe (or other verum) and control group; n.s.: not statistically significant; ^INot corresponding to WHO-definition of tumour response; ^{II}plural effusion indicates treatment site; ^{III}side effects in Helixor and doxycyclin group: pain in 6 and 14, fever in 3 and 6, burning sensation in 0 and 5 patients, respectively; difference statistically significant (p<0.05).
 “•”-outcomes relate to corresponding “•”-treatment group.

two reported symptomatic relief (reduction of nausea, vomiting, fatigue, diarrhoea, constipation, dyspnoea, and symptoms of ascites).

On *reduction of side effects of surgery, chemotherapy and radiation and related improvement of QoL* (Table 5): Of seven controlled trials, two RCTs and two N-RCTs showed a statistically significant positive effect [35;39;45;48], one RCT found improved QoL and prevention of lymphopenia, however, without computing statistical significance of the difference between the two comparison groups [47]; one small pilot RCT reported mixed results (no effect on QoL, a significant reduction of suppression of activated CD56+/CD69+/CD45+NK-cells, no effect on other immune cells) [46]; one RCT mentioned fewer side effects of 5-FU and a positive effect on QoL without giving details [44]. Furthermore, one of these trials reported that with additional mistletoe therapy the dosage of Cisplatin and Holoxan could be increased because of less intensive side effects. [35]

Tolerability was generally good. One case of urticaria and angioedema was described [45]. Otherwise, no major side effects or toxicity were reported. Minor dose-dependent and spontaneously subsiding symptoms included reactions at the injection site (swelling, induration, erythema, pruritus, local pain) and mild flu-like symptoms or fever. After intrapleural instillation mistletoe extract induced significantly fewer side effects than doxycyclin ([32], see Table 5)

DISCUSSION

Mistletoe therapy, especially AM preparations, is widely used to treat cancer patients in Central Europe. Most of the clinical trials report a benefit for survival, QoL, side-effects of toxic conventional therapies, or tumour remissions. Quality of the trials varies substantially; however, even most of the better-conducted and published trials show a beneficial effect. In detail:

Survival benefit (see Table 3) was assessed by most of the controlled trials. Half of them found a significant positive result; the other half did not reach or did not calculate significance or found no benefit, while none found a disadvantage. All of these trials received some amount of critique [29]: Among the best trials with significant positive effects (by Grossarth-Maticsek et al. [59]) were two RCTs embedded in a large cohort study that were small and had an epidemiological rather than a clinical trial design (for more details see [29]). This methodological approach is not well established, unfamiliar to most clinical researchers, and therefore raised concern [7;68]. Other trial publications mentioned major difficulties in patient recruitment or protocol violations [51;56-58], or had small and unequally distributed groups of patients [44]. Several trials had non-randomized designs, some of them carefully controlling for confounders. (Whether carefully conducted N-RCTs can be sufficient to yield valid results, is still the subject of controversial discussion. [69-71]) Survival benefit was usually reported under long treatment duration (several years) while the only trial with no benefit had a short treatment duration (months, with the maximum of one year only completed by 40% of the patients; for more details see

[29]). Dependency of survival benefit on length of mistletoe therapy was reported in one of the trials. [59] (This was also mentioned by two recent retrospective pharmaco-epidemiological cohort studies of mistletoe in breast cancer and melanoma. [72;73]) Furthermore, variability of results might be explained by differences in design, methodology and quality of the studies as well as differences in cancer sites and stages investigated. Whether possible survival benefit also depends on the type of mistletoe preparation, host tree, or dosage, cannot be seen in the reviewed trials; they often lacked detailed information and homogeneity for reliable inter-study comparison. These issues need further clarification.

Tumour remission (see Table 4) was investigated by three controlled trials. Two of them [42;43], an RCT and an N-RCT, adding mistletoe to chemotherapy and finding higher remission rates, lacked sufficient quality and transparency in design and presentation. One three-arm study [66], conducted by the German Cancer Research Centre, investigating sole mistletoe treatment, found surprisingly high tumour remission rates in all groups, even with placebo alone (20%). However, as the diagnosis was advanced lung cancer, the spontaneous remission rate of 20% seems unlikely [74], suggesting insufficient documentation or undocumented additional therapy. (Unnoticed co-intervention that contaminates results might be an underestimated and widely neglected hazard for the validity of clinical trials; for instance up to 90% of patients enrolled in conventional cancer trials also use CAM therapies [75].) Disease-free interval was investigated in one trial [60], which, however, may have been influenced by detection bias [29]. Overall, questions of tumour behaviour remain unclear in these controlled trials.

More reliable information on tumour remission is delivered by the cohort studies (see Table 6). Seven of these cohort studies were on solid tumours or on FL, four of them reporting substantial remission with no simultaneous conventional cytoreductive therapy (inoperable HCC, breast cancer pre-treated with chemotherapy, intracranial malignant tumour, FL). In a trial on pancreatic carcinoma, the intratumoural, endoscopic, ultrasound-guided, fine-needle injection of Helixor was combined with Gemcitabine treatment, and achieved tumour remission in 58% of patients, exceeding remission rates known with chemotherapy alone [33]. Notably, all four trials that documented remissions in solid tumours [31;33;63;64], other than the two trials with no remission [62;65], deviated from the common low escalating dosage and used high mistletoe doses from the beginning, and (in three studies) only once per week (due to chronobiological considerations; H. Werner, personal communication). Single-arm cohort studies, including phase II trials, that have no control group, need – besides careful outcome assessment and comprehensive documentation of all major covariables with potential influence on the tumour – an appraisal of spontaneous remissions. [76;77] Spontaneous remissions are common in a few tumour sites (e.g. CIN, renal cancer, melanoma, and lymphomas) but are extremely rare in most common cancers. [78;79] Accordingly, among the cohort studies

Table 5. Controlled Trials on Mistletoe Treatment in Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL (RCTs and N-RCTs each ordered by decreasing quality. See Table 1 and Table 2).

Author, year	Site	Stage	Intervention (evaluable patients)	Reduction of side effects of chemotherapy or radiation Outcome	P or CI	QoL (*during chemotherapy, radiation)	P or CI		
Randomized controlled trials									
Piao 2004 [45]	Breast, ovary, lung (NSCLC)	T1-4, N0-3, M0-1	<ul style="list-style-type: none"> Chemotherapy^I, Helixor A (115) Chemotherapy^I, Lentinan (109) 	Chemotherapy-related adverse events <ul style="list-style-type: none"> • 28 • 77 	not shown	*Increase in FLIC-score <ul style="list-style-type: none"> • ↑ 9 • ↑ 4.7 (p=0.014) 	*KPI increase in % of patients <ul style="list-style-type: none"> • 50 % • 32 % (p=0.0007) 	P=0.014 P=0.0007 P=0.002	
Auerbach 2005 [46]	Breast	T1-2, N0-1, M0	<ul style="list-style-type: none"> CMF, radiation, Helixor A (11) CMF, radiation, placebo (9) 	CMF-induced NK-cell decrease ↓ SCE-increase ↓ other immune markers: no difference	p=0.005 n.s.	*EORTC QLQ-C30	No difference, data not shown	not shown	
Grossarth 2001 [59]	Breast	IIIA-IIIB	<ul style="list-style-type: none"> Iscador (17) None (17) 			Self-regulation questionnaire (score 1-6)	<ul style="list-style-type: none"> • 2.92 → 3.7 • 2.87 → 2.99 	P=0.13	
Dold [66]	Lung	All stages	<ul style="list-style-type: none"> Iscador U or Qu, c.Hg; (114) Placebo (vitamin B) (113) Polyerga (110) 			Patients subjectively improved	<ul style="list-style-type: none"> • 59% • 45% • 43% 	<ul style="list-style-type: none"> • P=0.018 • (P=0.4) 	
Lange 1985 [35]	Lung, head and neck, ovary	Inoperable	<ul style="list-style-type: none"> Radiation, cisplatin, holoxan, Helixor (23) Radiation, cisplatin, holoxan (21) 	Nausea ↓ (p=0.005), vomiting ↓ (p=0.08), depression of myelopoiesis ↓ (leucocytes p=0.003)	p=0.005, p=0.08, p=0.003	*KPI	<ul style="list-style-type: none"> • 67% → 76% (p=0.0008^{II}) • 70% → 74% (p=0.12^{II}) 	not shown	
Borrelli 2001 [61]	Breast	IV	<ul style="list-style-type: none"> Iscador spezial (20) Placebo (10) 			Spitzer score questionnaire	<ul style="list-style-type: none"> • ~ 5 → 7.2 • ~ 5.2 → 4.8 	P<0,05	
Grossarth 2001 [59]	Breast, lung, colon, rectum, stomach	All stages	<ul style="list-style-type: none"> Iscador (39) None (39) 			Self-regulation questionnaire (score 1-6)	<ul style="list-style-type: none"> • 3.41 → 3.87 • 3.85 → 3.62 	P=0,02	
Kleeberg 2004 [60;67]	Melanoma	High risk primary (≥3MM) or LN+	<ul style="list-style-type: none"> Surgery, Iscador M (102) Surgery, IFN-α (240) Surgery, IFN-γ (244) Surgery (244/102) 			“Quality of life evaluation”	Result not shown	not shown	
Cazacu 2003 [44]	Colon, rectum	Dukes C or D	<ul style="list-style-type: none"> Surgery, 5-FU, Isorel A (29) Surgery, 5-FU (21) Surgery (14) 	5-FU side effects (% of patients) <ul style="list-style-type: none"> • 0% • 19% 	not shown	*“Quality of life”	“Improvement”; data not shown	not shown	
Enesel 2005 [47]	Gastro-intestinal	II-III	<ul style="list-style-type: none"> Surgery, Isorel A (40) Surgery (30) 	Prevention of Surgery-induced lymphocyte reduction	not shown	*KPI	<ul style="list-style-type: none"> • ↑ 22% (p<0.01^{II}) • ↓ 13% (p<0.05^{II}) 	*Score of Anxiety <ul style="list-style-type: none"> • ↓ 2,9 (p<0.01^{II}) • ↑ 1.5 (p<0.01^{II}) 	not shown

Table 5 (continued).

Author, year	Site	Stage	Intervention (evaluable patients)	Reduction of side effects of chemotherapy or radiation Outcome	P or CI	QoL (*during chemotherapy, radiation) Measurement scale and outcome	P or CI
Non-randomized controlled trials							
Büssing 2004 [39]	Breast (suspected)		<ul style="list-style-type: none"> • Surgery, Iscador M spezial (47) • Surgery (51) 	Prevention of surgery-associated inhibition of granulocyte function (PMA- and E.coli-stimulated oxidative burst)	P<0.0001, P<0.001		
Von Hagens 2005 [48]	Breast	I-II	<ul style="list-style-type: none"> • Surgery, CMF/EC, Iscador (33) • Surgery, CMF/EC (33) 	CMF/EC-induced lymphocyte decrease ↓, platelet decrease ↓	n.s., p=0.01	* EORTC QLQ-C30, B 23	Reduced increase of nausea/vomiting, general side effects of CMF/EC p=0.02 p=0.02

QoL: Quality of life; KPI: Karnofsky Performance Index; SCE: Sister Chromatid Exchange; †: Increase; ‡: decrease; P (p-value): Statistical significance of difference between mistletoe (or other verum) and control group; n.s.: not statistically significant; CMF: Cyclophosphamid, Methotrexat, 5FU; 5FU: 5-Fluorouracil; FA: Folic acid; I Chemotherapy: Breast Cancer: CAP, CAF; Ovarian cancer: CP, IeP; NSCLC: VP, MVIP. Cyclophosphamid (C), Cisplatin (P), 5-Fluorouracil (F), Vinorelbine (V), Mitomycin (M), Ifosfamid (I), Vindesine (Vi), Carboplatin (cP).

II statistical significance of pre-post-difference within each group;

“•”-outcomes relate to corresponding “•”-treatment group.

reviewed, spontaneous remissions might have occurred in CIN [34] or in FL [41].

Tumour remission under mistletoe therapy may depend on mode of application (local subcutaneous, intratumoural, intravenous, intrapleural), on chronobiological aspects (e.g. application once versus three times per week), and on dosage (slowly increasing versus high dosage from the beginning, as, for instance, antibodies against active ingredients are induced within weeks or months of treatment). These links are also suggested by anecdotal therapeutic reports, and are biologically plausible considering the substantial antitumoural, cytotoxic and pro-apoptotic VAE activity in vivo and in vitro that is partly inhibited by serum proteins and ML antibodies. [8;9] These issues should be investigated in more detail.

All seven trials investigating *reduction of side effects of toxic conventional treatments* (chemotherapy, radiation, surgery) (see Table 5) found a benefit. The methodologically best trial, an RCT conducted in China, investigated side effects of various chemotherapeutics and found significantly less adverse effects, better QoL and physical condition with mistletoe compared to the phytopharmakon Lentinan. [45] An unpublished German trial, small-sized but otherwise reasonably well-designed, showed fewer side effects of Cisplatin, Holoxan and radiotherapy with additional mistletoe therapy (less nausea and vomiting, better physical condition) and a positive effect on Holoxan and Cisplatin dosage (fewer dose reductions were necessary because of reduced side effects). [35] A small Austrian pilot trial reported no effect on QoL, less suppression of activated NK-cells and a trend towards less chromatin damage. This trial, well designed in many aspects, was severely underpowered for effect estimation, and the tested laboratory markers (SCE: Sister Chromatid Exchange, immune parameters) are more of experimental relevance than clinically well-established, and display high inter-individual variability. [46] The latter also applies to the N-RCT on surgery-associated inhibition of granulocyte function [39]; here, outcomes in two different hospitals (an AM hospital applying pre-operative mistletoe infusion, a COM hospital applying routine surgery only) were compared, matching for patient characteristics and length of surgery. Despite matching, residual differences of the two self-selected patient populations and settings (AM, COM) might also have affected the investigated immune function. [39] Biological plausibility of these side-effect reductions might lie in DNA-stabilizing properties of VAE [20-22]. These properties, however, seem not to attenuate the cytoreductive effects of radiotherapy and chemotherapy [35;42;43]; they were, rather, enhanced by VAE in vitro and in vivo. [9]

QoL (see Table 5) was investigated altogether in eleven controlled trials: Seven trials (one double blind [61]) found a benefit for mistletoe treatment, one reported a trend [59], one study (small, double-blind but unblinded by most patients [46]) found no difference, one did not present the results of an “improvement” [44]; one RCT cited “quality of life evaluation” in a pre-publication report [67] but did not mention it any more in the final publication [60]. Since assessment of QoL might be influenced by patients’ expectations,

Table 6. Single-Arm Cohort Studies (e.g. Phase II Trials) on Mistletoe Treatment in Cancer (ordered chronologically).

Author, Year	Treatment ^I	Preparation	Injection site	Dosage	Escalating dosage	Duration	Site ^{II}	Result ^{III}	CR	PR	NC	PD	QoL	n ^{IV}	L	M	N	O	P	Q
Solid tumours or lymphoma																				
Kuehn 2005 [41]	Iscaidor P (M, Qu occasionally)	Iscaidor P (M, Qu occasionally)	sc	0.01-30mg	Yes	mean 24 months	Follicular lymphoma	17% IIIa	25% IIIa	-	38%		24	(+)	(+)	+	+o IIIa	(+)	+	
Matthes 2005 [33]	Helixor M	Helixor M	it ^{IIa}	300-1000 mg	Yes	repeatedly	Pancreas	8%	50%	33%	8%	↗	12	(-)	(+)	(+)	-o	(+)	+	
Bar-Sela 2004 [62]	Abnobaviscum Qu	Abnobaviscum Qu	sc	3 x 0,15-15 mg/w	Yes	med. 14 w	Colon, Rectum	0	0	84%	16%	↗ IIIb	25	+	+	+	(+)	+	+	
Mabed 2004 [64]	Viscum fraxini	Viscum fraxini	sc	1 x 30 mg/w	No	med. 17 w	HCC	13%	9%	(39%) IIIc	39%		23	+	+	+	(-)	+	+	
Mahfouz 1999 [63]	Viscum fraxini	Viscum fraxini	sc or it	1 x 45 mg/w	No	18-136 w	Breast	8%	54%	35%	4%	↗	26	(+)	(+)	+	(+)	+	+	
Mahfouz 1998 [31]	Abnobaviscum Fr	Abnobaviscum Fr	sc	1 x 45 mg/w	No	17 w	Breast, Brain	27%	27%	27%	20%	↗	15	-	(-)	(+)	-	-	(+)	
Kjaer 1989 [65]	Iscaidor Qu or M, c.Cu	Iscaidor Qu or M, c.Cu	sc	Varying	Yes	med. 13/47 w	Kidney	0	0	14%	86%	↓	14	+	(+)	+	+o	(+)	+	
CIN																				
Portalupi 1995 [34]	Iscaidor M	Iscaidor M	sc	2 x 1 mg MLI /kg bw/w	No	16 w	CIN I-III	41%	27%	27%	5%		27	+	+	+	+	+	+	
Malignant effusion																				
Bar Sela 2006 [100]	Iscaidor M	Iscaidor M	ipe	10 mg	No	repeatedly	Ascites	Increase of interval between two successive paracenteses from 7 to 12 days, p=0.001 III d				↗ IIIc	23	(+)	(+)	+	(+)	+	+	
Werner 1999 [101]	Abnobaviscum Fr	Abnobaviscum Fr	ip	1 x 75 mg/w	No	3-8 w	Pleural effus.	88%				↗	32	+	+	+	-	(+)	(+)	
Stumpf 1994 [40]	Helixor A, M or P	Helixor A, M or P	ip	100-1000 mg each	Yes	repeatedly	Pleural effus.	61%	11%	22%			18	+	+	+	(+)	+	+	
Friedrichson 1985 [36]	Helixor	Helixor	ipe	100-1000 mg each	Yes	repeatedly	Ascites	70%				↗	12	(+)	(-)	+	-	(-)	+	

I sc: subcutaneous, it: intratumoural, ip: intrapleural, ipe: intraperitoneal; w: week, med.: median. IIa Endoscopic ultrasound-guided fine-needle injection.

II HCC: hepatocellular carcinoma, CIN: cervical intraepithelial neoplasia, effus.: effusion (malignant), Stage: advanced, except CIN; plural effusion and ascites indicates treatment site.

III CR: complete, PR: partial remission, NC: no change, PD: progressive disease, QoL: quality of life, ↗: improved, ↓: impaired; IIIa responses under mistletoe monotherapy, without concomitant oncologic cytoreductive therapies; IIIb symptomatic relief (40% of patients); IIIc undetermined response due to early death; III d median values, comparable abdominal circumference and symptom score or drained fluid before or during each paracentesis, respectively; IIIe Trend improvement in symptom score, especially abdominal pain, abdominal pressure, and waking up at night due to shortness of breath.

IV n: Number of participants.

V L: Well described patient characteristic and disease (diagnosis, stage, duration), prognostic factors

M Outcome parameter relevant and well described

N Well described intervention

O Concomitant therapies well described (o: concomitant conventional oncologic cytoreductive therapies in some of the patients)

P Outcome clearly described, temporal relationship between applied therapy and observed outcome precisely described

Q Selection of patients excluded

blinding is a relevant issue. However, due to local skin reaction (rubor, pruritus, induration) and mild flu-like symptoms, blinded subcutaneous mistletoe applications are usually unblinded by 80% - 100% of patients and physicians, as confirmed in two recent double-blind RCTs [46;80]. For this reason, the ethics committee for an RCT on non-anthroposophic mistletoe extracts [81] did not approve a double-blind design. When reliable blinding is questionable, a possibility is to apply active or pseudo-active control treatments that might generate similar expectations. This was done in the trial conducted in China when the control group received Lentinan, a polysaccharide cancer drug popular in China and Japan [45]; it was also done in a three-arm trial when two study groups received either vitamin B or Polyerga [66]. In both trials, QoL results in the mistletoe groups were rated significantly higher than in the control groups. – Besides, blinding of outcome assessment should be conducted whenever possible, or QoL assessment should be combined with other biological parameters that are less prone to subjectivity, as done in some of the mistletoe trials. Finally, the possibility of blinding of other application routes, like intravenous infusions, should be checked in future trials and done if possible.

Safety aspects: Mistletoe therapy was well tolerated in the reviewed trials. Impairment of QoL in one cohort study was due to progressive cancer disease. [65] Good tolerability was also shown in other investigations. [82] Currently, a phase I study at the NC-CAM/NCI is investigating safety, toxicity and drug interactions between mistletoe extract and Gemcitabine. [83] A first interim report found good tolerability, with neither dose-limiting toxicity of the mistletoe extract nor any effects on the plasma concentration of gemcitabine. [84] Allergic reactions can occur, and a few case reports of anaphylactic reactions exist [82;85;86]. Recently, a list of serious side effects of mistletoe therapy was published [87;88] but turned out to be erroneous interpretations of reports not referring to mistletoe therapy (for details see [89] or [7]). Enhancement of brain metastases was discussed in preliminary reports [90;91] on the melanoma trial by Kleeberg et al. 2004 [60]. The data were not confirmed in the final publication [60], and may have resulted from detection bias [29;92]. Still, they gave rise to an elaborate GEP-conform, retrospective multi-centre study in Germany and Switzerland, conducted by the Dermatology Department of the University of Freiburg: in 686 consecutive patients (329 mistletoe, 357 controls) with melanoma stage II or III, treated in 35 randomly chosen centres, no tumour enhancement could be observed in mistletoe-treated patients, while incidence of brain metastases (multiple adjusted analysis), brain metastases-free survival, disease-free survival, and overall survival were all statistically significant in favour of the mistletoe group. [72] Regarding initial high-dose therapy, as reported in the Egyptian trials [31;63;64], safety aspects might have to be taken into account because high dosages might produce much stronger local reactions and flu-like symptoms. Furthermore, especially in Central Europe, prior mistletoe exposure through the widespread use of mixed herbal remedies or teas is possible and often not known to

the patients; therefore adverse reactions to initial high mistletoe dosages are a theoretical possibility.

Strength and weakness of the review

The validity of this review largely depends on the primary trials. There are substantial weaknesses in several of the reviewed studies; however, some of the more recent ones, in particular, were reasonably well conducted. Strengths and weaknesses of most of the reviewed trials, such as potential performance bias, detection bias, attrition bias etc., have been described previously (see [29]) and are summarized and updated in Table 1, Table 2 and Table 6. Blinding of therapy was attempted in only two trials [46;61]; however, blinded application of mistletoe extracts is unblinded by most of the patients [46;80], which is why reliability of *pro forma* blinding might be questionable (see above).

In order to minimize publication bias, all unpublished trials were included and a comprehensive search was conducted, including personal contacts with approximately 150 experts in the field worldwide, most of them from Europe [6;7]. We consider it unlikely that important rigorous trials, especially RCTs, remained unnoticed, at least in Europe; however, we cannot exclude that we missed trials in distant, non-European countries, or small cohort studies unknown to our contacted experts and not listed in the screened databases. The two trials that were excluded because of validity concerns (see result section) reported results in favour of mistletoe treatment; therefore no positive bias is induced by these exclusions. One further N-RCT, a feasibility trial, not included in this review because it did not present quantifiable results, also reported results in favour of mistletoe therapy (fewer side effects and improved QoL in breast cancer patients undergoing chemotherapy with CMF or EC) [93]. Inclusion of different sorts of trials (RCT, N-RCT, cohort study) does not bias this review, since they are clearly indicated in Table 2 - Table 6 and explicitly identified in the text.

For this review, blinded quality assessment was impossible, since most trials were previously known to the authors.

Clinical relevance and further research recommendations

All reported endpoints are clinically relevant. Some application and dosage modalities, especially in cohort studies, deviated from general recommendations.

In the reviewed trials, mistletoe therapy was mostly applied in non-AM and non-CAM settings. In AM settings, mistletoe therapy is usually part of a complex clinical approach that may include, besides COM remedies, further AM medicines, art and movement therapy, therapeutic massage and counselling for physical, mental, social and spiritual issues. [6;7;94] These multi-modal treatments claim to focus on the “whole” patient, trying to improve his or her inherent self-healing abilities. Comprehensive prospective trials on the whole system of AM cancer treatment were recently conducted by the Universities of Uppsala and Bern. The Swedish study compared QoL of breast cancer patients in AM and COM settings. A prospective matched-pair design was chosen because an RCT was

not feasible (funding from the Swedish Cancer Society and other sources did not cover expenses that would have included patients staying in an AM clinic). While AM patients had lower QoL-scores at study entrance, they significantly improved during AM therapy and, after one year, were superior compared to COM-treated patients, who showed no significant change of QoL. [95] The Swiss AM cancer study, a project by the Swiss National Science Foundation, consisted of three study modules including a three-armed randomized controlled trial investigating the benefit of additional AM or psychosocial treatment. This RCT had to be stopped as not enough patients at the Institute of Medical Oncology in Bern could be enrolled. [96]

Common difficulties with patient recruitment seem to be frequent in European mistletoe trials. [9] In a feasibility study by the University of Heidelberg, out of 1,922 patients receiving surgical treatment for breast cancer only 29 (1,5%) could have participated in an RCT. [97] Two larger RCTs that were finally brought to completion took eight and nine years of patient recruitment despite multi-centre designs and sample size re-calculation to reduce the required number of patients. [60;66] Reasons for hampered patient recruitment were multiple, e.g. not fulfilling inclusion criteria, preference or objection towards mistletoe treatment, general rejection of study participation or of randomized treatment allocation, participation in other studies, or logistical reasons. This issue has to be carefully considered in future trials.

Regarding the widespread use and the potential anti-tumour benefit of VAE, widely investigated especially in vitro and in animal models [8;9], clinical research should be further intensified and its quality further improved. This process would clearly benefit from public funding to enable more extensive and clinically detailed research. Future studies should take into account the methodological limitations and potential biases of the reviewed mistletoe trials (see also [29]). They should further explore the results of the cohort studies, and clarify the impact of different modalities of mistletoe applications (dosage, location, intervals, duration) on the outcome in different therapeutic situations. Furthermore, since a biomedical paradigm – viewing mind and body as separate – has been perceived as an additional violation by patients and may increase their suffering [98], multimodal systems (see above) should also be investigated and patients' perspectives evaluated in order to gain insights into ways of meeting their need of holistic, multimodal care. Appropriate research methods may include comparison trials of different complex treatment systems, high quality observational studies, or carefully performed qualitative research. [99] These complex approaches, however, require strong commitment by the research community, and often require more preparatory effort than conventional clinical trials. [99]

CONCLUSION

Quality of clinical trials on mistletoe therapy varies substantially, but has improved during recent years. With regard to quality of studies and consistency of results, the best evidence concerning efficacy of mistle-

toe therapy seems to exist for improvement of QoL and reduction of side effects of cytoreductive therapies (chemotherapy, radiation) – limited by the fact that the interventions are not blinded, and cannot be reliably blinded. Survival benefit is possible; conventional RCTs on this issue had varying results and best evidence relies mostly on small trials using epidemiological methodology unfamiliar to most scientists and less widely accepted [59;72;73]. In relation to tumour remission, the controlled trials are inconclusive; cohort studies describe tumour remissions mostly with high dosage and local application; they should be further explored. Tumour remission seems to depend on dosage and on mode of application. Mistletoe application seems safe except for rare allergic reactions.

As several reasonably well-conducted studies indicate beneficial effects, and results of preclinical research are promising, further properly designed trials should be encouraged to investigate clinical efficacy and its possible dependency on mode of application. Also, considering the widespread use of mistletoe among cancer patients as well as many patients' apparent need for complementary medicine and holistic care, research activities should be increased. Future controlled studies should take into account the methodological limitations and potential biases of these previous mistletoe trials.

Acknowledgements: We are grateful to the contacted AM experts for valuable help with literature searches, to authors of mistletoe trials for providing additional information, and to Harald J. Hamre for helpful comments. We are also grateful to the colleagues of our international working group that prepared the preceding mistletoe review [29] partly incorporated into this study. This study was funded by the Complementary Medicine Evaluation Program (PEK) of the Swiss Federal Office for Public Health; updating and manuscript preparation was funded by IFAEMM e.V. Freiburg/Bad Krozingen.

REFERENCES

1. Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V et al. Use of complementary and alternative medicine in cancer patients: a European survey. *Ann Oncol* 2005; Advance Access published online on February 2:doi:10.1093/annonc/mdi110.
2. Schwabe U, Paffrath D, (eds.). *Arzneiverordnungsreport 2005*. Heidelberg: Springer Verlag, 2005.
3. Petru E, Schmied P, Petru C. Komplementäre Maßnahmen bei Patientinnen mit gynäkologischen Malignomen unter Chemo- und Hormontherapie - Bestandsaufnahmen und kritische Überlegungen für die Praxis. [Complementary Measures Used by Patients With Gynecologic Cancers Undergoing Cytotoxic or Hormonal Chemotherapy]. *Geburtshilfe Frauenheilkd* 2001; 61:75-8.
4. Weis J, Bartsch HH, Hennies F, Rietschel M, Heim M, Adam G et al. Complementary medicine in cancer patients: demand, patients' attitudes and psychological beliefs. *Onkologie* 1998; 21:144-9.
5. Steiner R. *Introducing Anthroposophical Medicine* (1920). Hudson, NY, USA: Anthroposophic Press, 1999.
6. Kienle GS, Kiene H, Albonico HU. Health Technology Assessment Report: Anthroposophic Medicine. Complementary Medicine Evaluation Program (PEK) of the Swiss Federal Office for Public Health. 2005.
7. Kienle GS, Kiene H, Albonico HU. *Anthroposophic Medicine: Effectiveness, Utility, Costs, Safety*. Stuttgart, New York: Schattauer Verlag, 2006.

8. Büssing A, (ed.). Mistletoe. The Genus *Viscum*. Amsterdam: Hardwood Academic Publishers, 2000.
9. Kienle GS, Kiene H. Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen. Stuttgart, New York: Schattauer Verlag, 2003.
10. Franz H, Ziska P, Kindt A. Isolation and properties of three lectins from mistletoe (*Viscum album* L.). *Biochem J* 1981; 195:481-4.
11. Winterfeld K, Kronenthaler A. Zur Chemie des blutdrucksenkenden Bestandteils der Mistel. (*Viscum album*). *Arch Pharm* 1942; 280:103-15.
12. Winterfeld K, Bijnen AB. Viscotoxin, ein neuer Inhaltsstoff der Mistel (*Viscum album* L.). *Liebigs Ann Chem* 1948; 561:107-15.
13. Klett CY, Anderer FA. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from *Viscum album* extract. *Arzneim-Forsch /Drug Res* 1989; 39 (II)(12):1-20.
14. Mueller EA, Anderer FA. A *Viscum album* oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. *Cancer Immunol Immunother* 1990; 32:221-7.
15. Urech K, Scher JM, Hostanska K, Becker H. Apoptosis inducing activity of viscin, a lipophilic extract from *Viscum album* L. *J Pharm Pharmacol* 2005; 57:101-9.
16. Janssen O, Scheffler A, Kabelitz D. In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). *Arzneim -Forsch /Drug Res* 1993; 43(II)(11):1221-7.
17. Büssing A, Suzart K, Bergmann J, Pfüller U, Schietzel M, Schweizer K. Induction of apoptosis in human lymphocytes treated with *Viscum album* L. is mediated by the mistletoe lectins. *Cancer Lett* 1996;(99):59-72.
18. Büssing A, Vervecken W, Wagner M, Wagner B, Pfüller U, Schietzel M. Expression of mitochondrial Apo2.7 molecules and Caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. *Cytometry* 1999; 37(2):133-9.
19. Büssing A, Schaller G, Pfüller U. Generation of reactive oxygen intermediates (ROI) by the thionins from *Viscum album* L. *Anticancer Res* 1998; 18:4291-6.
20. Büssing A, Azhari T, Ostendorp K, Lehnert A, Schweizer K. *Viscum album* L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. *Eur J Cancer* 1994; 30A(12):1836-41.
21. Büssing A, Regnery A, Schweizer K. Effects of *Viscum album* L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. *Cancer Lett* 1995;(94):199-205.
22. Büssing A, Jungmann H, Suzart K, Schweizer K. Suppression of sister chromatid exchange-including DNA lesions in cultured peripheral blood mononuclear cells by *Viscum album* L. *J Exp Clin Cancer Res* 1996; 15(2):107-14.
23. Kiene H. Klinische Studien zur Misteltherapie karzinomatöser Erkrankungen. Eine Übersicht. *Therapeutikon* 1989; 3(6):347-53.
24. Kleijnen J, Knipschild P. Mistletoe treatment for cancer - review of controlled trials in humans. *Phytomedicine* 1994; 1:255-60.
25. University of Texas Center for Alternative Medicine Research in Cancer. Mistletoe. <http://www.sph.uth.tmc.edu/utcam/therapies/mistletoe.htm>. 1999.
26. National Cancer Institute. Mistletoe extracts (PDQ®). <http://cancer.net.ncl.nih.gov/cancertopics/pdq/cam/mistletoe/HealthProfessional/page1>. 2004.
27. Stauder H, Kreuser E-D. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. *Onkologie* 2002; 25:374-80.
28. Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomized clinical trials. *Int J Cancer* 2003; 107:262-7.
29. Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer - a systematic review on controlled clinical trials. *Eur J Med Res* 2003; 8:109-19.
30. Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking Systematic Reviews of Research on Effectiveness. CRD'S Guidance for those Carrying Out or Commissioning Reviews. CRD Report Number 4 (2nd Edition). University of York: NHS Centre for Reviews and Dissemination, 2001.
31. Mahfouz MM, Ghaleb HA, Zawawy A, Scheffler A. Significant tumor reduction, improvement of pain and quality of life and normalization of sleeping patterns of cancer patients treated with a high dose of mistletoe. *Ann Oncol* 1998; 9(S2):129.
32. Kim M-H, Park Y-K, Lee S-H, Kim S-C, Lee S-Y, Kim C-H et al. Comparative study on the effects of a *Viscum album* (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion. 51th Meeting of The Korean Association of Internal Medicine. Translation by Helixor Heilmittel GmbH. *Korean Journal of Medicine* 1999; 57(Suppl. II):S121.
33. Matthes H, Schad F, Buchwald D, Schenk G. Endoscopic ultrasound-guided fine-needle injection of *Viscum album* L. (mistletoe; Helixor M) in the therapy of primary inoperable pancreas cancer: a pilot study. *Gastroenterology* 2005; 128(4 Suppl. 2):433, T 988.
34. Portalupi E. Neoadjuvant treatment in HPV-related CIN with Mistletoe preparation (Iscador). Dissertation Universität Pavia 1991/1992. 1995.
35. Lange O, Scholz G, Gutsch J. Modulation der subjektiven und objektiven Toxizität einer aggressiven Chemotherapie mit Helixor. Unpublished Report. 1985.
36. Friedrichson UKH. Intraperitoneal instillation of *Viscum album* (L.) extract (mistletoe) for therapy and malignant ascites. Department of Radiology/Oncology, Community Hospital of Herdecke, University Witten/ Herdecke. Unpublished Report. 1995.
37. Jach R, Basta A. Iscador QuS and human recombinant interferon alpha (Intron A) in cervical intraepithelial neoplasia (CIN). *Przegląd Lekarski* 1999; 56(1):86-8.
38. Jach R, Basta A, Szczudrawa A. Role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 with concurrent HPV infection. *Ginekol Pol* 2003; 74(9):729-35.
39. Büssing A, Bischof M, Hatzmann W, Bartsch F, Soto-Vera D, Fronk E-M et al. Beeinflussung der Granulozytenfunktion durch einmalige perioperative Mistelextrakt-Infusion. *Deutsche Zeitschrift für Onkologie* 2004; 36:148-53.
40. Stumpf C, Schietzel M. Intrapleurale Instillation eines Extraktes aus *Viscum album* [L.] zur Behandlung maligner Pleuraergüsse. *Tumordiagnose u Therapie* 1994;(15):57-62.
41. Kuehn JJ. Misteltherapie bei malignen Lymphomen - Neue Erkenntnisse und Erfahrungen im Rahmen einer prospektiven Kasuistikserie bei Patienten mit follikulären Non-Hodgkin-Lymphomen. In: Scheer R, Bauer R, Becker H, Fintelman V, Kemper FH, Schilcher H, editors. Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung. Essen: KVC Verlag, 2005: 477-489.
42. Douwes FR, Wolfrum DI, Migeod F. Ergebnisse einer prospektiv randomisierten Studie: Chemotherapie versus Chemotherapie plus "Biological Response Modifier" bei metastasierendem kolorektalen Karzinom. *Krebsgeschehen* 1986; 18(6):155-63.

43. Douwes FR, Kalden M, Frank G, Holzhauer P. Behandlung des fortgeschrittenen kolorektalen Karzinoms. *Deutsche Zeitschrift für Onkologie* 1988; 20(3):63-7.
44. Cazacu M, Oniu T, Lungoci C, Mihailov A, Cipak A, Klinger R et al. The influence of Isorel on the advanced colorectal cancer. *Cancer Biother Radiopharm* 2003; 18(1):27-34.
45. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. *Anticancer Res* 2004; 24(1):303-9.
46. Auerbach L, Dostal V, Václavik-Fleck I, Kubista E, Rosenberger A, Rieger S et al. Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiven randomisierten doppelblinden Studie. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. *Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung*. Essen: KCV Verlag, 2005: 543-554.
47. Enesel MB, Acalovschi I, Grosu V, Sbarcea A, Rusu C, Dobre A et al. Perioperative application of the *Viscum album* extract Isorel in digestive tract cancer patients. *Anticancer Res* 2005; 25:4583-90.
48. von Hagens C, Loewe-Mesch A, Kuehn JJ, Abel U, Gerhard I. Prospektive kontrollierte nicht randomisierte Machbarkeits-Studie zu einer postoperativen simultanen Mistel-/Chemotherapie bei Patientinnen mit Mammakarzinom - Ergebnisse zu Rekrutierbarkeit, Immunparametern, Lebensqualität und Verträglichkeit. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, editors. *Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung*. Essen: KVC Verlag, 2005: 567-578.
49. Salzer G, Danmayr E, Wutzlhofer F, Frey S. Adjuvante Iscador-Behandlung operierter nicht kleinzelliger Bronchuskarzinome. *Dtsch Zschr Onkol* 1991; 23(4):93-8.
50. Majewski A, Bentele W. Über Zusatzbehandlung beim weiblichen Genitalkarzinom. *Zentralbl Gynäkol* 1963; 85(20):696-700.
51. Gutsch J, Berger H, Scholz G, Denck H. Prospektive Studie beim radikal operierten Mammakarzinom mit Polychemotherapie, Helixor und unbehandelter Kontrolle. *Dtsch Zschr Onkol* 1988;(4):94-100.
52. Schuppli R. Die adjuvante Behandlung des malignen Melanoms mit Iscador c.Hg. In: Jungi WF, Senn H-J, editors. *Krebs und Alternativmedizin II*. Berlin - Heidelberg: Springer-Verlag, 1990: 84-87.
53. Salzer G, Havelec L. Rezidivprophylaxe bei operierten Bronchuskarzinompatienten mit dem Mistelpräparat Iscador - Ergebnisse eines klinischen Versuchs aus den Jahren 1969-1971. *Onkologie* 1978; 1(6):262-7.
54. Fellmer Ch, Fellmer KE. Nachbehandlung bestrahlter Genitalkarzinome mit dem *Viscum-album*-Präparat "Iscador". *Krebsarzt* 1966; 21(3):174-85.
55. Salzer G. 30 Jahre Erfahrung mit der Misteltherapie an öffentlichen Krankenanstalten. In: Leroi R, editor. *Misteltherapie. Eine Antwort auf die Herausforderung Krebs*. Stuttgart: Verlag Freies Geistesleben, 1987: 173-215.
56. Salzer G, Denck H. Randomisierte Studie über medikamentöse Rezidivprophylaxe mit 5-Fluorouracil und Iscador beim resezierten Magenkarzinom - Ergebnisse einer Zwischenauswertung. *Krebsgeschehen* 1979; 11(5):130-1.
57. Salzer G, Havelec L. Adjuvante Iscador-Behandlung nach operiertem Magenkarzinom. Ergebnisse einer randomisierten Studie. *Krebsgeschehen* 1983; 15(4):106-10.
58. Salzer G. Prospektiv randomisierte Studie: Operiertes Magenkarzinom - Adjuvante Behandlung mit Iscador. *Dtsch Zschr Onkol* 1988; 20(4):90-3.
59. Grossarth-Maticsek R, Kiene H, Baumgartner S, Ziegler R. Use of Iscador, an extract of European mistletoe (*Viscum album*), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. *Altern Ther Health Med* 2001; 7(3):57-78.
60. Kleeberg UR, Suciú S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-a2b versus rIFN-γ versus Iscador M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis. *Eur J Cancer* 2004; 40:390-402.
61. Borrelli E. Evaluation of the quality of life in breast cancer patients undergoing lectin standardized mistletoe therapy. *Minerva Medica* 2001; 92(Suppl. 1):105-7.
62. Bar-Sela G, Haim N. Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. *Med Oncol* 2004; 21(3):251-4.
63. Mahfouz MM, Ghaleb HA, Hamza MR, Fares L, Moussa L, Moustafua A et al. Multicenter open labeled clinical study in advanced breast cancer patients. A preliminary report. *Journal of the Egyptian Nat Cancer Inst* 1999; 11(3):221-7.
64. Mabed M, El-Helw L, Sharma S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. *Br J Cancer* 2004; 90:65-9.
65. Kjaer M. Mistletoe (Iscador) therapy in stage IV renal adenocarcinoma. *Acta Oncol* 1989; 28(4):489-94.
66. Dold U, Edler L, Mäurer HCh, Müller-Wening D, Sakellariou B, Trendelenburg F et al. Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Stuttgart, New York: Georg Thieme Verlag, 1991.
67. Eggermont A, Kleeberg UR, Ruiter DJ, Suciú S. European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. In: American Society of Clinical Oncology, editor. *American Society of Clinical Oncology Educational Book*. Baltimore, MD: Lippincott Williams & Wilkins, 2001: 88-93.
68. Diskussion: Mistel in der Krebstherapie. *Deutsches Ärzteblatt* 2004; 101(30):A2125-A2127.
69. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med* 2000; 342:1887-92.
70. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. *N Engl J Med* 2000; 342(1878):1886.
71. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. *Br Med J* 1998; 317:1185-90.
72. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (*Viscum album L.*) extract. *Arzneim -Forsch /Drug Res* 2005; 55(1):38-49.
73. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (*Viscum album L.*) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, epidemiologischen Kohortenstudie in Deutschland und der Schweiz. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (*Viscum album L.*) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center,

- comparative, epidemiological cohort study in Germany and Switzerland]. *Arzneim -Forsch /Drug Res* 2004; 54(8):456-66.
74. Kappauf H, Gallmeier WM, Wünsch PH, Mittelmeier H-O, Birkmann J, Büschel G et al. Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. *Ann Oncol* 1997; 8:1031-9.
 75. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. *J Clin Oncol* 2004; 22(23):4810-5.
 76. Kienle GS, Hamre HJ, Portalupi E, Kiene H. Improving the quality of therapeutic reports of single cases and case series in oncology – criteria and checklist. *Altern Ther Health Med* 2004; 10:68-72.
 77. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* 2000; 92(3):205-16.
 78. Papac RJ. Spontaneous regression of cancer. *Cancer Treatment Reviews* 1996; 22:395-423.
 79. Heim ME, Schwarz R. (eds.) *Spontanremission in der Onkologie. [Spontaneous regression in oncology]*. Stuttgart, New York: Schattauer Verlag, 1998.
 80. Rostock M, Huber R. Randomized and double-blind studies - demands and reality as demonstrated by two examples of mistletoe research. *Forsch Komplementärmed* 2004; 11(Suppl 1):18-22.
 81. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. *Eur J Cancer* 2001; 37:23-31.
 82. Stein GM, Berg PA. Adverse effects during therapy with mistletoe extracts. In: Büssing A, editor. *Mistletoe. The Genus Viscum*. Amsterdam: Hardwood Academic Publishers, 2000: 195-208.
 83. Mansky PJ, Grem J, Wallerstedt DB, Monahan BP, Blackman MR. Mistletoe and Gemcitabine in patients with advanced cancer: A model for the phase I study of botanicals and botanical-drug interactions in cancer therapy. *Integr Cancer Ther* 2003; 2(4):345-52.
 84. Mansky PJ et al. Mistletoe extract/gemcitabine combination treatment: An interim report from the NCCAM/NCI phase I study in patients with advanced solid tumors. *ASCO Annual Meeting*, 2005.
 85. Bauer C, Oppel T, Rueff F, Przybilla B. Anaphylaxis to viscotoxins of mistletoe (*Viscum album*) extracts. *Ann Allergy Asthma Immunol* 2005; 94(1):86-9.
 86. Hutt N, Kopferschmitt-Kubler M, Cabalion J, Purohit A, Alt M, Pauli G. Anaphylactic reactions after therapeutic injection of mistletoe (*Viscum album L.*). *Allergol Immunopathol (Madr)* 2001; 29(5):201-3.
 87. Ernst E. Mistletoe for cancer? *Eur J Cancer* 2001; 37:9-11.
 88. Ernst E. Anthroposophical Medicine: A systematic review of randomised clinical trials. *Wien Klin Wochenschr* 2004; 116(4):128-30.
 89. Kienle GS, Hamre HJ, Kiene H. Anthroposophical Medicine: A systematic review of randomised clinical trials. *Wien Klin Wochenschr* 2004; 116:407-8.
 90. Hausschild A. Therapie des malignen Melanoms - Qualitätssicherung und Perspektiven. *Onkologie* 1996; 2:412-22.
 91. Silver S. Trial results warn of dangers in the use of mistletoe extract. *Lancet Oncol* 2001; 2:196.
 92. Kiene H. EORTC mistletoe study. *Lancet Oncol* 2001; 2(332):333.
 93. Loewe-Mesch A. Chemotherapie des Mammakarzinoms. Was können wir von einer supportiven Mistletoetherapie erwarten? Ergebnisse einer Feasibility-Studie. 36. *Medizinische Woche Baden-Baden.*: 2002.
 94. Ritchie J, Wilkinson J, Gantley M, Feder G, Carter Y, Formby J. A model of integrated primary care: anthroposophical medicine. London: National Centre for Social Research Department of General Practice and Primary Care, St Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London 2001.
 95. Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E. Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. *Acta Oncol* 2004; 43(1):27-34.
 96. von Rohr E, Pampallona S, van Wegberg B, Hürny Ch, Bernhard J, Heusser P et al. Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. *Schweiz Med Wochenschr* 2000; 130:1173-84.
 97. Gerhard I, Abel U, Loewe-Mesch A, Huppmann S, Kuehn JJ. Problematik randomisierter Studien in der Komplementärmedizin dargestellt am Beispiel der Mistletoetherapie bei Patientinnen mit Mammakarzinom. [Problems of randomized studies in complementary medicine demonstrated in a study on mistletoe treatment of patients with breast cancer]. *Forsch Komplementärmed* 2004; 11:150-7.
 98. Arman M, Rehnsfeldt A, Lindholm L, Hamrin E. The face of suffering among women with breast cancer - being in a field of forces. *Cancer Nurs* 2002; 25(2):96-103.
 99. Nahin RL, Straus SE. Research into complementary and alternative medicine: problems and potential. *Br Med J* 2001; 322:161-4.
 100. Bar-Sela G, Goldberg H, Beck D, Amit A, Kuten A. Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a *Viscum album* extract. *Anticancer Res* 2006; 26:709-14.
 101. Werner H, Mahfouz MM, Fares L, Fouad F, Ghaleb HA, Hamza MR et al. Zur Therapie des malignen Pleuraergusses mit einem Mistletoe-Präparat. *Der Merkurstab* 1999; 52(5):298-301.

Received: August 3, 2006 / Accepted: January 23, 2007

Address for correspondence:

Dr. med. Gunver S. Kienle
 Institut für angewandte Erkenntnistheorie und medizinische Methodologie e.V.
 Schauinslandstraße 6
 D-79189 Bad Krozingen
 Tel.: +49-7633-806682
 Fax: +49-7633-806696
 e-mail: gunver.kienle@ifaemm.de